PCF Challenge Awards for Metastatic, Lethal Prostate Cancer - LOI
RFA  https://res.cloudinary.com/pcf/image/upload/v1644441433/2022_Challenge_Award_RFA_2.9.22_nlvkqz.pdf

Research proposals in the following topic areas are preferred:

• Immunotherapy for the treatment of metastatic, lethal prostate cancer.
• Targeted radionuclide therapy for advanced prostate cancer.
• New systemic precision treatments for metastatic, lethal prostate cancer including those targeting the currently ‘undruggable’.
• First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
• Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents.
• Correlative research around either clinical trials of novel agents or strategies or standard of care.
• Determinants of survivorship that will improve the lives of patients with metastatic prostate cancer.
• Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
• Tumor microenvironment signaling related to cancer progression including the immune component.
• New data science technologies for analysis of genomic information to advance precision medicine.
• Research proposals that identify or intervene in biological determinants, health care access policies, or other causes of prostate cancer incidence and mortality disparity are highly encouraged.